Clinical-stage biopharmaceutical company developing conditionally active biologics (CAB) for cancer treatment.
BioAtla, Inc., operating as a clinical stage biopharmaceutical company headquartered in San Diego, California, specializes in developing highly targeted antibody-based therapies designed to combat solid tumor cancers. The company's flagship product candidate, BA3011, represents a novel approach as a conditionally active biologic (CAB) antibody-drug conjugate (ADC) specifically tailored for treating soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC targeting multiple solid tumor types such as NSCLC, melanoma, and ovarian cancer. Moreover, the company is developing BA3071, a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at treating a wide spectrum of cancers including renal cell carcinoma, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer.
Founded in 2007, BioAtla, Inc. has cultivated a reputation for innovation in the field of oncology therapeutics, leveraging its expertise to pioneer advancements in antibody engineering and drug conjugation technologies. The company's research and development efforts are underpinned by a commitment to precision medicine, striving to deliver therapies that offer enhanced efficacy and reduced side effects compared to traditional cancer treatments.
BioAtla's strategic focus extends beyond current product candidates, encompassing a robust pipeline aimed at addressing a broad range of cancer types with significant unmet medical needs. Through strategic collaborations and partnerships, the company continues to expand its capabilities in antibody engineering and therapeutic development, positioning itself as a key player in the evolving landscape of cancer treatment.
With its headquarters situated in San Diego, a hub renowned for biotechnology innovation, BioAtla, Inc. is strategically positioned to capitalize on the region's rich talent pool and collaborative research environment. The company remains dedicated to advancing its mission of transforming cancer care through cutting-edge science and pioneering biopharmaceutical solutions.